Company
StickyCell has developed and patented a pioneering blood testing system, ‘LAFA’ (leukocyte adhesive function assay), for analysing the human immune system and vulnerability to diseases.
Our immune system induces inflammation when circulating leukocytes are activated and become “stickier” on the blood vessel wall for translocation into surrounding tissues. The LAFA testing system assesses the leukocytes’ ability to cause inflammation, using microfluidic chips and microfluidic fluorescent image-capturing system to measure the leukocyte’s “stickiness” and the potential to cause inflammation, thus delivering unique scientific insights and machine-learning outcomes for early detection, prevention and personalised treatment of various human diseases.
Description
StickyCell, an innovative biotechnology company, is developing a novel blood test platform for disease diagnosis, precision medicine and drug development
Technology
1) novel diagnostic blood tests for inflammatory and infectious diseases, to improve treatment outcomes and reduce treatment costs;
2) drug companion diagnostics blood tests that can identify drug responders, assess drug efficacy precisely, improve treatment outcomes, reduce adverse side effects and minimise drug wastage;
3) a drug screening tool for drug discovery, that can improve the accuracy of drug metabolism research and the success rate of drug development
